IP Library Granted Patent US 9,345,721
Granted Patent B2
US 9,345,721 · App. 14/087,930 · Granted May 24, 2016

Use of lactulose in the treatment of autism

Inventors: Joan M. Fallon (Bronxville, NY); Richard Feltenstein (New Rochelle, NY)
Assignee: Curemark, LLC
A61K31/7016A61K31/045A61K31/7012
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,345,721
App. No.
14/087,930
Granted
May 24, 2016
Kind
B2
Abstract

A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

Claims (13)

1. A method for treating an individual diagnosed with an autistic disorder, the method comprising administering a therapeutically effective amount of lactulose and mannitol to the individual, wherein administration of the lactulose follows administration of an antibiotic, and wherein administration of lactulose increases the number of lactobacilli and bifidobacteria in a gut flora.

2. The method of claim 1 , wherein the individual has a gastrointestinal disorder, a neurological disorder, or a combination thereof.

3. The method of claim 1 , wherein the lactulose is administered in an amount of about 0.4 g/kg lactulose per dose.

4. The method of claim 1 , wherein the lactulose is administered in an amount of about 0.3 g/kg lactulose per dose.

5. The method of claim 1 , wherein the lactulose is administered approximately two to five times per day.

6. The method of claim 1 , wherein the lactulose is administered in a form selected from the group consisting of a powder, a liquid solution, a syrup, and a combination thereof.

7. The method of claim 1 , wherein a level of ammonia is decreased in the blood of the individual.

8. The method of claim 1 , wherein a level of ammonia is decreased in the gastrointestinal tract of the individual.

9. The method of claim 1 , wherein a level of ammonia is decreased in the nervous system of the individual.

10. The method of claim 1 , wherein the lactulose reverses ammonia poisoning caused by the administration of antibiotics that leave a residue in the gastrointestinal tract of the individual.

11. The method of claim 1 wherein the mannitol is administered in an amount of about 0.1 g/kg mannitol per dose.

12. The method of claim 1 , wherein administration of the lactulose immediately follows administration of the antibiotic.

13. The method of claim 1 , wherein the antibiotic is amoxicillin-clavulanate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2014
From: FALLON, JOAN M.; FELTENSTEIN, RICHARD
To: CUREMARK, LLC
Reel/Frame 031933/0208 →
Continuity (5)
Continuation 13204881 · Aug 8, 2011
Division 12049613 · Mar 17, 2008
Division 11468379 · Aug 30, 2006
Provisional Application 60712551 · Aug 30, 2005
Related Publication 20140187512A1 · Jul 3, 2014